Even immunotherapy approaches such as PD-1:PD-L1 blockade, which are more widely efficacious than ALK and EGFR inhibitors, do not benefit a substantial proportion of patients with NSCLC (3, 13, 38, 39). Here, ALK is linked to non-small cell lung carcinoma.